L&C Bio Shares Jump on New Fix for Ozempic Face

L&C Bio stock hit 64,600 won on Thursday, continuing a strong five day run for the South Korean firm. Investors are backing the company as it moves into the market for correcting the gaunt facial appearance often caused by GLP 1 weight loss medications like Ozempic.

The proposed product, called MegaAdipoECM, uses donated human fat to restore volume to the face. This process acts as a natural alternative to synthetic fillers. While South Korean regulations previously treated donated fat as waste, a legal change in 2026 opened the door for this technology. The company plans to target markets in South Korea, China, and the United States once it launches, which is expected by late 2027.

This growth story provides a rare bright spot during a volatile year for Korean equities. As traders navigate broader market uncertainty, interest in specific biotech breakthroughs remains high. With patents already secured in major regions, L&C Bio is betting that its low cost raw materials will create a significant advantage in the aesthetics industry.

Investors are now watching to see if the company can maintain this momentum ahead of its commercial launch. Analysts have set a high one year price target of 99,000 won, though the stock has seen wide price swings over the past twelve months.